Tilray (TLRY) AI Stock Analysis

• Market Cap: $1.16B
• Dividend Yield: N/A
• Average Volume (3M): 52.83M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.54
• Revenue Growth: 2.31%
• EPS Growth: -726.17%
• Country: US
• Employees: 2,650
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 0.00
• Shares Outstanding: 1,122,863,200
• 10 Day Avg. Volume: 42,429,364
• 30 Day Avg. Volume: 52,834,514
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.18
• Price to Sales (P/S): 0.34
• P/FCF Ratio: -2.17
• Enterprise Value/Market Cap: 1.30
• Enterprise Value/Revenue: 1.39
• Enterprise Value/Gross Profit: 4.83
• Enterprise Value/Ebitda: -0.50
• 1Y Price Target: $1.95
• Price Target Upside: 51.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): $858.73M

• Rating: 40 Underperform
• Price Target: $0.98 ▼(-24.11% Downside)

Tilray's overall stock score is low, primarily due to its poor financial performance and weak technical indicators. The company's significant losses and liquidity issues overshadow the positive aspects of its earnings call. Valuation metrics further contribute to the low score, with a negative P/E ratio and no dividend yield.

Positive Factors

Revenue Growth

The consistent revenue growth, particularly in the Cannabis segment, indicates strong market demand and effective sales strategies, supporting long-term business expansion.

International Expansion

Tilray's focus on international expansion, especially in Germany, positions it to capture new markets and diversify revenue streams, enhancing its global footprint.

Debt Reduction

Effective debt management and strong cash reserves improve financial stability, providing flexibility for future investments and strategic initiatives.

Negative Factors

Negative Cash Flow

Persistent negative cash flows indicate challenges in cash generation, which could hinder operational capabilities and investment in growth opportunities.

Declining Gross Margins

Decreasing gross margins may pressure profitability, suggesting inefficiencies in cost management or pricing strategies that need addressing for sustainable growth.

Permitting Issues

Regulatory challenges in key markets like Portugal can obstruct international operations and growth plans, potentially limiting market expansion and revenue.

Tilray Business Overview & Revenue Model

Company Description

Tilray, Inc. is a global leader in the cannabis industry, focused on the cultivation, production, and distribution of medical and recreational cannabis products. Founded in 2013 and headquartered in Nanaimo, British Columbia, Tilray operates across multiple sectors including pharmaceutical, consumer packaged goods, and hemp-based wellness products. The company offers a diverse range of products, including dried flower, oils, capsules, edibles, and beverages, catering to both adult-use and medical cannabis markets.

How the Company Makes Money

Tilray generates revenue primarily through the sale of cannabis products in both the medical and recreational markets. Key revenue streams include direct-to-consumer sales through its own distribution channels and partnerships with licensed retailers. The company also engages in wholesale distribution to other cannabis companies and dispensaries. Additionally, Tilray has been expanding its presence in the global market by entering into strategic partnerships and joint ventures, such as collaborations with major alcohol brands and pharmaceutical companies, which provide further avenues for revenue generation. The company's investments in research and development of innovative products and its focus on international expansion are also significant contributors to its earnings.

Tilray Financial Statement Overview

Summary

Tilray's financial performance is weak, with significant challenges in profitability and cash flow. The income statement shows persistent losses and declining revenue, while the balance sheet reflects low leverage but negative returns. Cash flow analysis reveals liquidity issues, with negative cash flows and poor cash conversion.

Income Statement

Tilray's income statement reveals significant challenges, with negative net profit margins and declining revenue growth. The TTM data shows a gross profit margin of 28.77%, but the net profit margin is deeply negative at -278.12%, indicating substantial losses. Revenue growth is negative, suggesting a contraction in sales. Overall, the company is struggling with profitability and growth.

Balance Sheet

The balance sheet shows a relatively low debt-to-equity ratio of 0.15 in the TTM period, indicating conservative leverage. However, the return on equity is negative, reflecting ongoing losses. The equity ratio is not provided, but the available data suggests financial stability in terms of debt management, albeit with profitability concerns.

Cash Flow

Cash flow analysis highlights significant issues, with negative operating and free cash flows. The TTM data shows a free cash flow growth rate of -31.63%, indicating worsening cash generation. The operating cash flow to net income ratio is negative, reflecting poor cash conversion. Overall, the cash flow situation is concerning, with limited liquidity.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.08B	1.13B	1.07B	844.72M	792.12M	619.67M
Gross Profit	311.03M	330.11M	304.33M	197.95M	147.26M	148.77M
EBITDA	-2.98B	-2.92B	-99.25M	-1.72B	-310.61M	-297.41M
Net Income	-3.01B	-3.00B	-333.80M	-1.96B	-601.05M	-443.75M
Balance Sheet
Total Assets	2.08B	2.90B	5.91B	5.92B	6.87B	6.03B
Cash, Cash Equivalents and Short-Term Investments	264.83M	351.78M	354.98M	604.16M	524.29M	488.47M
Total Debt	231.29M	451.09M	527.75M	794.89M	786.36M	938.66M
Total Liabilities	561.99M	860.49M	1.22B	1.44B	1.27B	1.56B
Stockholders Equity	1.54B	2.07B	4.69B	4.47B	5.55B	4.46B
Cash Flow
Free Cash Flow	-119.70M	-174.98M	-81.96M	-17.37M	-266.39M	-100.93M
Operating Cash Flow	-83.01M	-129.81M	-42.11M	10.65M	-223.45M	-53.99M
Investing Cash Flow	28.48M	-64.11M	174.88M	-384.04M	-27.14M	55.67M
Financing Cash Flow	120.54M	183.20M	-102.45M	94.50M	161.60M	150.09M

Tilray Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.29
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TLRY, the sentiment is Neutral. The current price of 1.29 is above the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.37, and above the 200-day MA of 0.85, indicating a neutral trend. The MACD of -0.12 indicates Positive momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 37.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TLRY.

Tilray Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRON	64 Neutral	C$1.33B	26.54	3.34%	―	22.20%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDL	49 Neutral	$448.05M	―	-7.82%	―	1.76%	18.31%
EVGN	43 Neutral	$10.63M	-0.54	―	―	-29.78%	88.96%
IMCC	42 Neutral	$6.72M	-2.36	-93.87%	―	-0.74%	81.49%
HYFM	42 Neutral	$8.35M	―	-30.93%	―	-26.84%	-0.16%
TLRY	40 Underperform	$1.16B	―	-85.59%	―	2.31%	-726.17%

Tilray Corporate Events

Tilray Stockholders Meeting Approves Key Proposals

On November 18, 2025, Tilray Brands, Inc. held its annual stockholders meeting where several key proposals were voted on. The re-election of John Herhalt as Class I director and the ratification of PricewaterhouseCoopers LLP as the independent accounting firm were approved. However, the proposal to amend the company’s governance structure to declassify the board and change director removal provisions did not pass, indicating mixed support for governance changes among stockholders.

The most recent analyst rating on (TLRY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Tilray stock, see the TLRY Stock Forecast page.

Tilray Releases Investor Presentation November 2025

Tilray Brands, Inc. has released an investor presentation on November 17, 2025, which is available on their website. The presentation is provided for informational purposes and is not intended to be filed under the Securities and Exchange Act of 1934.

The most recent analyst rating on (TLRY) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Tilray stock, see the TLRY Stock Forecast page.

Tilray Brands Reports Record Revenue and Profitability

Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company operating in the cannabis, beverage, and wellness industries, with a presence in Canada, the United States, Europe, Australia, and Latin America.

Tilray’s Earnings Call: Growth Amid Challenges

The recent earnings call for Tilray showcased a balanced sentiment, highlighting significant achievements in revenue growth and international expansion, while also addressing challenges in the Beverage segment and permitting delays in Portugal. The company demonstrated resilience and strategic foresight amidst these mixed outcomes.